Participated · Series A · Aug 2021

DnaNudge develops consumer genetics testing services and a portable clinical‑grade point‑of‑care RT‑PCR testing platform. Its CE‑marked CovidNudge is a sample‑to‑result COVID‑19 RT‑PCR test that delivers accurate results in just over an hour without a laboratory or manual sample pre‑processing and is in use in healthcare settings worldwide. The platform supports high multiplexing (72 testing wells per cartridge) and can test simultaneously for SARS‑CoV‑2 variants, Flu A, Flu B, RSV and markers indicating genetic risk for key health conditions. DnaNudge also operates a consumer Nutrition service that maps genetic profiles to nutrition‑related traits (obesity, diabetes, hypertension, cholesterol) to guide personalised shopping and is shortly extending into personalised skincare. The company has secured wholesale supply agreements with major international healthcare companies and provides regular pool testing for organisations including the Royal Opera House, the London Symphony Orchestra and Glyndebourne. The recent $60M Series A will fund accelerated global deployment of its rapid genetic testing solutions and scale availability in the US, Japan, Europe and other key territories.

Participated · Equity · Feb 2018

Moderna is building a broad portfolio of vaccines while advancing a late-stage clinical pipeline. The company plans to grow its seasonal vaccine offering from three approved products today to as many as six by 2028. Management projects that total revenue will rise 10 % in 2026. Cash generated from existing vaccine products is earmarked for investment in oncology and rare disease programs, laying the groundwork for further growth in 2027 and 2028. Early-stage pipeline investments are expected to begin maturing in 2029 and beyond. Access to newly secured credit strengthens the firm’s liquidity to support these initiatives.